Compare · CRVS vs RCUS
CRVS vs RCUS
Side-by-side comparison of Corvus Pharmaceuticals Inc. (CRVS) and Arcus Biosciences Inc. (RCUS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRVS and RCUS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- RCUS is the larger of the two at $3.54B, about 3.3x CRVS ($1.06B).
- Over the past year, CRVS is up 194.0% and RCUS is up 221.6% - RCUS leads by 27.6 points.
- RCUS has been more active in the news (12 items in the past 4 weeks vs 7 for CRVS).
- RCUS has more recent analyst coverage (16 ratings vs 8 for CRVS).
- Company
- Corvus Pharmaceuticals Inc.
- Arcus Biosciences Inc.
- Price
- $12.67+0.76%
- $28.17+3.41%
- Market cap
- $1.06B
- $3.54B
- 1M return
- -2.99%
- +17.84%
- 1Y return
- +193.97%
- +221.58%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- 2018
- News (4w)
- 7
- 12
- Recent ratings
- 8
- 16
Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and activate various immune cells, as Phase III clinical trial of CPI-006 for COVID-19. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/II clinical trial for adenosine, an immune checkpoint. Its preclinical stage products include CPI-182, an antibody to block neutrophil function and migration, and myeloid derived suppressor cells; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Arcus Biosciences Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Latest CRVS
- Director Moore David Scott bought $250,236 worth of shares (21,700 units at $11.53) (SEC Form 4)
- SEC Form 4 filed by Director Clark Ian T
- SEC Form 4 filed by Director Grais Linda
- SEC Form 4 filed by Director Thompson Peter A.
- SEC Form 4 filed by Director Van Den Broek Richard
- Corvus Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China
- President and CEO Miller Richard A Md bought $83,453 worth of shares (6,932 units at $12.04) (SEC Form 4)
- Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by Corvus Pharmaceuticals Inc.
Latest RCUS
- SEC Form 144 filed by Arcus Biosciences Inc.
- Director Lambert Nicole was granted 5,700 shares, increasing direct ownership by 15% to 43,000 units (SEC Form 4)
- Director Kaneko Yasunori was granted 5,700 shares, increasing direct ownership by 28% to 25,700 units (SEC Form 4)
- Director Machado Patrick was granted 5,700 shares, increasing direct ownership by 15% to 44,300 units (SEC Form 4)
- General Counsel Tang Carolyn C. exercised 34,090 shares at a strike of $2.57, increasing direct ownership by 23% to 184,607 units (SEC Form 4)
- Director Lacey David L. was granted 5,700 shares, increasing direct ownership by 8% to 76,652 units (SEC Form 4)
- Director Ribas Antoni was granted 5,700 shares, increasing direct ownership by 15% to 44,300 units (SEC Form 4)
- Director Perlman Andrew J was granted 5,700 shares, increasing direct ownership by 13% to 48,325 units (SEC Form 4)
- Director Falberg Kathryn E was granted 5,700 shares, increasing direct ownership by 15% to 44,300 units (SEC Form 4)
- Arcus Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders